Copy to clipboard 
Dimension Inx closed a $12 million Series A Round. The company will use the funding to advance the development of therapeutics focused on functional organ restoration, and expand their manufacturing capabilities. In the near term, the company will use the funds to support the commercial launch of their first product, CMFlex.
In addition to their Series A funding, Dimension Inx also announced that they have received FDA 510(k) clearance for CMFlex, reportedly the first 3D-printed regenerative bone graft product cleared by FDA. CMFlex is a 3D-printed regenerative bone graft product. As a ready-to-use flexible ceramic for oral and maxillofacial indications, CMFlex may improve clinician workflow and reduce surgical case time for clinicians, while restoring healthy bone.
Caralynn Nowinski Collens, M.D., CEO of Dimension Inx, said, “FDA clearance is a major milestone for our platform, and validates the work we’ve put into developing our product over the past two years. CMFlex is a product that represents our unique approach to restoring functionality in the body: it’s a dynamic collaboration between biology, material composition, microstructure, and macroarchitecture. We’re excited by the interest we’ve already received from surgeons who recognize the importance of a ready-to-use solution that is easy to handle and accelerates healing to improve patient outcomes.”
Dimension Inx plans to bring new 3D-printable materials and medical devices to market to aid tissue repair and bone regeneration in orthopedic applications.
Source: Dimension Inx
